NurExone Expands U.S. Engagement at Boston Life Sciences Events
News related to:NurExone Biologic Inc · 1 min read
NurExone Biologic Inc., a biotechnology company developing exosome-based regenerative therapies, is expanding its U.S. engagement by participating in four major life sciences events in Boston from September 22-25, 2026. The company’s CEO, Dr. Lior Shaltiel, and R&D Director, Dr. Tali Kizhner, will be key speakers at these conferences, which are expected to attract participants from across the global life sciences sector, including investors, scientists, and representatives from leading pharmaceutical companies.
Dr. Shaltiel will participate in three conference programs.
Dr. Kizhner will also represent NurExone as a speaker at the 8th Exosome-Based Therapeutics Development Summit. She will contribute to discussions around translating exosome therapeutics toward clinical and commercial development. The company’s CEO will also attend the invitation-only World Medical Innovation Forum, presented by Mass General Brigham and Bank of America, which will take place from September 22-23, 2026.
NurExone’s participation in these events comes as the company continues to advance its lead therapeutic candidate, ExoPTEN, toward clinical development for acute spinal cord injury. The company is also pursuing initiatives intended to support future U.S. manufacturing and commercial activities. Its recently announced U.S. manufacturing memorandum of understanding with Made Scientific reflects this objective.
In a separate development, NurExone has entered into a non-exclusive investor relations agreement with RedChip Companies, Inc., an arm’s-length service provider based in Maitland, Florida. RedChip will write, produce, and distribute a 30-second television advertisement for the company as part of a two-week national television campaign expected to include 40 airings on either Fox Business National TV or CNBC National TV. The campaign is expected to commence on September 28, 2026, and is subject to acceptance by the TSX Venture Exchange. The company will pay RedChip a one-time cash fee of US$65,000.
NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage.